6UAN image
Entry Detail
PDB ID:
6UAN
EMDB ID:
Title:
B-Raf:14-3-3 complex
Biological Source:
PDB Version:
Deposition Date:
2019-09-11
Release Date:
2019-09-25
Method Details:
Experimental Method:
Resolution:
3.90 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:14-3-3 zeta
Chain IDs:A, B (auth: Z)
Chain Length:247
Number of Molecules:2
Biological Source:Spodoptera aff. frugiperda 1 BOLD-2017
Polymer Type:polypeptide(L)
Description:Serine/threonine-protein kinase B-raf
Chain IDs:C (auth: B), D (auth: C)
Chain Length:768
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP C SER modified residue
Ligand Molecules
Primary Citation
Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases.
Science 366 109 115 (2019)
PMID: 31604311 DOI: 10.1126/science.aay0543

Abstact

Raf kinases are important cancer drug targets. Paradoxically, many B-Raf inhibitors induce the activation of Raf kinases. Cryo-electron microscopy structural analysis of a phosphorylated B-Raf kinase domain dimer in complex with dimeric 14-3-3, at a resolution of ~3.9 angstroms, shows an asymmetric arrangement in which one kinase is in a canonical "active" conformation. The distal segment of the C-terminal tail of this kinase interacts with, and blocks, the active site of the cognate kinase in this asymmetric arrangement. Deletion of the C-terminal segment reduces Raf activity. The unexpected asymmetric quaternary architecture illustrates how the paradoxical activation of Raf by kinase inhibitors reflects an innate mechanism, with 14-3-3 facilitating inhibition of one kinase while maintaining activity of the other. Conformational modulation of these contacts may provide new opportunities for Raf inhibitor development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures